Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
HUGO Series 🌟
HUGO-GT™ (Rare Disease Research)
HUGO-Ab™ (Antibody Discovery)
MouseAtlas Model Library
Flash Sales
Research Models
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
Cell Line Models
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Services
Preclinical Efficacy
Neuroscience
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Ophthalmology
Oncology
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
Genetically Engineered Animals
Knockout Mice
Transgenic Mice
Knockin Mice
Knockout Rats
Knockin Rats
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Breeding & Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Modalities
Gene Therapy
AI-Powered AAV Discovery
Oligonucleotide Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
About Us
Corporate Overview
Facility Overview
Animal Health & Welfare
Health Reports
Our Partners
Careers
Contact Us
Login

Inducible Cre Mouse Enhances Pancreatic Gene Knockouts

Cyagen Technical Content Team | July 13, 2025
Pdx1-CreERT2 Mouse
Target islet cell gene expression with the Pdx1-CreERT2 strain. Ideal for pancreatic development and β-cell studies in academic and biotech research.
Pdx1-CreERT2 Mouse
Contents
01. PDX1 Gene: A Key to Pancreatic Organogenesis and β-cell Function 02. Pdx1-CreERT2 Mice Exhibit Higher Pancreas-Specific Recombination Efficiency than Pdx1-Cre Mice 03. Cre Recombinase Exhibits Limited Expression in the Duodenum and Thymus 04. The Pdx1-CreERT2 Mouse Model Exhibits Good Tissue Specificity 05. Summary 06. References

The Cre-Lox system allows for gene knockout/knockin in specific cells/tissues, with the timing of its expression is determined by the promoter. To further achieve dual control of gene expression in terms of both time and space, ligand-dependent CreER recombinase was developed. CreER is composed of Cre recombinase fused with the hormone-binding domain of the estrogen receptor. In the absence of the estrogen analog tamoxifen, the recombinase is mainly present in the cytoplasm. Only under the action of tamoxifen can the recombinase enter the cell nucleus and exert its recombination function. CreERT2 is an upgraded version of the CreER recombinase with three point mutations (G400V/M543A/L544A) in the estrogen-binding domain, which reduces background activity when uninduced while increasing tamoxifen sensitivity and induction efficiency. Today, we introduce the improved pancreas-specific cre driver mouse line — the Pdx1-CreERT2 mouse model (Product No.: C001537).

PDX1 Gene: A Key to Pancreatic Organogenesis and β-cell Function

The PDX1 gene encodes a protein that is a major regulator of pancreatic organogenesis, β-cell maturation and maintenance, and normal insulin function. Activation of the PDX1 gene promotes insulin release and the expression of important genes in β-cells, making it necessary for pancreatic stem cells to differentiate into pancreatic β-cells. Thus, PDX1 is an important target for gene or replacement therapies for diabetes.[1]

Research has found that PDX1 protein maintains the characteristics and functions of β-cells by inhibiting the differentiation of α-cells, and pancreatic β-cells can survive and undergo β-to-α cell reprogramming in the absence of PDX1.[2] PDX1 is specifically expressed in early pancreatic epithelium and plays a role in proliferation and differentiation during development. At the adult stage, PDX1 is essential for hormne production in β-cells. PDX1 is one of the earliest expressed transcription factors during pancreatic development and continues to be expressed during β-cell maturation.[1,3] Besides its expression in β-cells and some δ-cells, it is also expressed in the gastrointestinal tract (such as the duodenum) and the central nervous system during development.[4-5]

Figure 1. The role of PDX1 in pancreatic organogenesis and β-cell maturation.[1]

Pdx1-CreERT2 Mouse Model for Targeted Pancreatic Research

Cyagen has independently developed the Pdx1-CreERT2 mouse (Product No.: C001537) using gene editing technology to provide a liver-specific Cre driver mouse line with exceptional temporal control for gene research and preclinical studies. The Pdx1-CreERT2 mouse model expresses the CreERT2 recombinase under the control of the mouse Pdx1 gene regulatory elements. Once Pdx1-CreERT2 mice are crossed with mice containing loxP sites, tamoxifen induction can trigger Cre recombinase-mediated recombination between the loxP sites in the pancreas of the offspring.

Tamoxifen Induction of Pancreas Tissue-Specific Gene Recombination

Without tamoxifen treatment, CreERT2 recombinase primarily resides in the cytoplasm. Only when tamoxifen is administered does the CreERT2 recombinase enter the cell nucleus and exert its recombination activity. When Pdx1-CreERT2 mice are crossed with mice containing loxP sites, tamoxifen induction can trigger sequence recombination between loxP sites mediated by Cre recombinase in the pancreatic cells of the offspring. It’s important to note that without tamoxifen treatment, there may be some leakage of CreERT2 recombinase expression before induction. The insertion site of the Cre recombinase gene expression cassette in this strain is located on chromosome 5, so breeding with gene-edited mice targeting genes on the same chromosome as the Cre mouse should be avoided when conducting mating.

Pdx1-CreERT2 Mice Exhibit Higher Pancreas-Specific Recombination Efficiency than Pdx1-Cre Mice

Figure 2. Expression of Cre recombinase in the pancreas shown by fluorescence microscopy.

After Pdx1-CreERT2 mice are crossed with ROSA26-LSL-tdTomato mice, which conditionally express tdTomato fluorescent protein, the expression of CreERT2 recombinase is induced in the double transgenic offspring by treatment with tamoxifen or corn oil. The fluorescence microscopy results show a significant amount of tdTomato fluorescence signal in the pancreas of the tamoxifen-treated group, indicating high recombinase activity. Additionally, compared to non-inducible Pdx1-Cre mice, the Pdx1-CreERT2 mice exhibit significantly higher recombination efficiency in the pancreas.

Cre Recombinase Exhibits Limited Expression in the Duodenum and Thymus

Figure 3. Fluorescence microscopy demonstrating the expression of Cre recombinase in the duodenum and thymus.
Following the previous method of crossing Pdx1-CreERT2 mice with ROSA26-LSL-tdTomato mice, the expression of CreERT2 recombinase is induced in the offspring by treatment with tamoxifen or corn oil. The fluorescence microscopy results show partial red fluorescence signals in the duodenal villi and thymus of the tamoxifen-treated group, demonstrating additional tissues that may be affected by the induction of gene modification.

The Pdx1-CreERT2 Mouse Model Exhibits Good Tissue Specificity

Figure 4. Immunofluorescence (IF) shows no demonstrable expression of Cre recombinase in other tissues tested, including the stomach, uterus, ovaries, lungs, liver, and brain.
When Pdx1-CreERT2 mice are crossed with ROSA26-LSL-tdTomato mice and their offspring are treated with tamoxifen or corn oil, no significant recombination signals are detected in the stomach, uterus, ovaries, lungs, liver, and brain tissues of either the tamoxifen-treated group or the corn oil-treated group. This indicates that the Pdx1-CreERT2 mouse exhibits good tissue specificity, with high targeting of the pancreas and detargeting of other major tissues.

Summary

The Pdx1-CreERT2 mouse model (Product No.: C001537) has demonstrated high expression of Cre recombinase in the pancreas, with minimal fluorescence signals observed in the duodenum and thymus indicating trace recombination events. No recombination signals are detected under fluorescence microscopy in the stomach, uterus, ovaries, lungs, liver, and brain — indicating detargeting of other major tissues. Therefore, the Pdx1-CreERT2 mouse model demonstrates good specificity for use in targeted genetic research on pancreatic islet cell tissues.

References

[1] Ebrahim N, Shakirova K, Dashinimaev E. PDX1 is the cornerstone of pancreatic β-cell functions and identity. Front Mol Biosci. 2022 Dec 15;9:1091757.

[2] Gao T, McKenna B, Li C, Reichert M, Nguyen J, Singh T, Yang C, Pannikar A, Doliba N, Zhang T, Stoffers DA, Edlund H, Matschinsky F, Stein R, Stanger BZ. Pdx1 maintains β cell identity and function by repressing an α cell program. Cell Metab. 2014 Feb 4;19(2):259-71.

[3] Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA. Development of the human pancreas from foregut to endocrine commitment. Diabetes. 2013 Oct;62(10):3514-22.

[4] Ma J, Chen M, Wang J, Xia HH, Zhu S, Liang Y, Gu Q, Qiao L, Dai Y, Zou B, Li Z, Zhang Y, Lan H, Wong BC. Pancreatic duodenal homeobox-1 (PDX1) functions as a tumor suppressor in gastric cancer. Carcinogenesis. 2008 Jul;29(7):1327-33.

[5] Perez-Villamil B, Schwartz PT, Vallejo M. The pancreatic homeodomain transcription factor IDX1/IPF1 is expressed in neural cells during brain development. Endocrinology. 1999 Aug;140(8):3857-60.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Humanized ABCA4 Models Advance RNA & Gene Editing
From F9 to Function: Validating a New Preclinical Model for Hemophilia B Drug Development
Accelerating the Search for a Cure: A New Preclinical Model for Methylmalonic Acidemia
Driving Translational Success: A Strategic Analysis of C3 and C5 Humanized Mouse Models for Next-Generation Drug Development
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Models
HUGO-Ab™ (Antibody Discovery)HUGO-GT™ (Rare Disease Research)MouseAtlas Model LibraryResearch Models
Services
NeuroscienceOphthalmologyOncologyMetabolic & Cardiovascular DiseasesAutoimmune & Inflammatory
About Us
Corporate OverviewFacility OverviewAnimal Health & WelfareHealth ReportsOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research